SlideShare a Scribd company logo
Vaccines' Investment Mapping
V6.08.11.2022
Afrigen South African hub
+
Biovac
Institute Pasteur Tunis -
Tunisia
BioGeneric Pharma –
Egypt
TBD -
Kenya
nstitute Pasteur Dakar -
Senegal
Biovaccines -
Nigeria
end-to-end
Spokes & Current industrial initiatives for Covid-19 vaccines in Africa
Fill&Finish
mRNA plans to 3rd parties
mRNA spokes
Algeria
Morocco
Ghana
Uganda
Rwanda
Source: CHAI and UNICEF
Botswana
mRNA vaccine production
Kenya Moderna Moderna and Kenya signed a MoU to build mRNA facility
Rwanda Senegal,
South Africa
BioNTech
BioNTech announced a plan to develop the capacity to produce upcoming
mRNA-based vaccines
Ghana BioNTech BioNTech to establish manufacturing plants for fill, finish and packaging
Other Industrial Partnerships
Algeria
Saidal & Sinovac 200M capacity, started in 2021, then move up the value chain
Saidal & Gamaleya Sputnik V starting Sept 2021 ($40M capacity)
Sothema & Sinopharm $60M capacity
South Africa
Aspen & J&J F&F started in 2021. 2022 plan to manufacture under Aspen’s brand name
NantSA & Immunity Bio To set up a new plant to produce vaccines
Rubic Consortium & Dyadic
& WITS
to establish a new plant
Biovac & Pfizer started a tech transfer in 2021 for AU member states
Egypt
Eva Pharma EgyVax currently under Ph 1
Vacsera & Sinovac Produced ~30M doses of Sinovac vaccine
Minipharma & Gamaleya To produce 40M doses per year
Botswana NantWorks to establish a new plant and to produce Corbevax by 2026
Financial &Technical contributions to African vaccine local production outside of the
mRNA Tech Transfer Hub
Institution Content of the support
AFD Granted €1.8M to IPD for a feasibility study
Afreximbank
To support infrastructural facilities and initiate vaccine
production in Ogun State, Nigeria for €180M
Belgium €4.5M for NRA strengthening in Senegal and €0,5M to Rwanda
Germany
BMZ (KfW) granted €20M to IPD’s MADIBA project and €1M to
develop vaccine production capacity
BMZ (GIZ) committed €5M to Ghana to advance local
manufacturing + 0.18M +€2.7M co-financing from EU to
strengthen the FDA
BMZ (GIZ) committed €11.7M for establishing a local vaccine in
Rwanda and €24M to support EAC Centre of Excellence for
vaccine
DEG support to Aspen with €144M (J&J vaccine)
€51M to South Africa to support vaccination campaigns and the
development of a vaccine supply chain (incl. regulatory
strengthening)
€10M to support ACDC and promote regulatory framework
€250M promotional loan to Afreximbank + €12.2M to the
prep4vac project
Institution Content of the support
FCDO FCDO supported the business case development and
feasibility assessment for Aspen and IPD
IFC coalition
IPD €13M grant for MADIBA project
Rwanda and Morocco to conduct diagnostic and feasibility
studies
Biovac to raise €136M
Aspen contracted €644M loan
Team Europe &
EU
IPD received €6.7M to support the MADIBA project
Granted €3.1M to Rwanda
US Gov
US DFC granted €2.9M to IPD to support the MADIBA project
Aspen received €181M to produce J&J vaccine for the African
continent
World
Bank
Attributed Granted €27M to Biovaccines for vaccine
manufacturing plant
Spokes & current industrial initiatives for Covid-19 vaccines in Latin America
Source: CHAI and UNICEF mRNA spokes mRNA plans to 3rd
parties
Fill&Finish End to End
Argentina - Sinergium Biotech
Brazil –
Bio-Manguinho
Venezuela
Peru
Mexico
Cuba
mRNA vaccine production
Brazil HDT Bio & SENAI CIMATEC HDT Bio granted to SENAI CIMATEC a non-exclusive license to produce its
RNA vaccine
Eurofarma & BioNtech to produce 100M doses
Other Industrial Partnerships
Argentina
Richmond Lab & Gamaleya
Research Institute
to produce Sputnik
mAbxience & AstraZeneca mAbxience to produce AstraZeneca’s drug substance to be FF in Mexico
Sinergium & Sinopharm to produce 1M doses /week
Brazil
Fiocruz & AstraZeneca for 100.4M doses capacity
Biomm & CanSino to distribute the vaccine in Brazil
União Química & Gamaleya to set up FF capacity
Instituto Butantan &
Sinovac
to produce 1M doses
Cuba BioCubaFarma developed Abdala and Soberana 2 vaccine
Mexico
Birmex & Gamaleya
Birmex & AstraZeneca
Peru Plans to build a plant in 2023 to produce Sputnik V and other vaccines
Venezuela
Espromed-Bio & Center for
Genetic Engineering and
Biotechnology
Espromed-Bio to produce 4M doses from the Center for Genetic
Engineering and Biotechnology
Source: CHAI and UNICEF
Pakistan - National
Institute of Health
Vietnam - Polyvac
Bangladesh –
Incepta
Indonesia - Biofarma
Malaysia
Sri Lanka
Philippines
Thailand
mRNA spokes mRNA plans to 3rd
parties
Fill&Finish End to End
mRNA vaccine production
Bangladesh Globe Biotech to develop its own mRNA vaccines. Under Ph1
Thailand Bionet consortium composed of Pennsylvania, North Carolina, California-
Davis, Chulalongkorn, IVI. Currently under Ph 2 CT
Vietnam Vinbiocare & Arcturus
Other Industrial Partnerships
Bangladesh
Incepta to produce Corbevax
Incepta & Sinopharme MoU to produce 5M doses
Indonesia
Bio Farma & Children’s Hospital to produce Texas Children’s Hospital’ vaccine
Bio Farma & Sinovac
Malaysia
Pharmaniaga & Sinovac to distribute then produce 14M doses
Solution Biologic & Cansino
Philippines Glovax Biotech & Eubiologics to produce 40M doses
Sri Lanka
State Pharmaceutical Corporation
& Sinovac
to produce 9M doses
Thailand Siam Bioscience & AstraZeneca
Vietnam
IVAC stops Ph 3 CT of its COVIVAC due to volunteer shortages
IVAC & CIGB to produce Cuban Abdala vaccine
Nanogen to develop a recombinant vaccine that is still under Ph 3 trial
Vabiotech & Gamaleya
Vabiotech& Shionogi
AIC & Shionogi
Polyvac & Gamaleya
Current industrial initiatives for Covid-19 vaccines in India
Source: CHAI and UNICEF mRNA spokes mRNA plans to 3rd
parties
Fill&Finish End to End Drug substance
mRNA vaccine production
Gennova Gennova Gennova is developing mRNA vaccine
Other Industrial Partnerships
Biological E
Biological E & Texas Children’s Hospital
Biological E & J&J Biological E & J&J to collaborate to produce 600M doses/year
Serum Institute
of India
SII & Novavax
SII & Gamaleya Research Institute
SII & AstraZeneca
Bharat Biotech
Bharat Biotech To develop an inactivated vaccine
Bharat Biotech & Haffkine Bharat Biotech to licence Haffkine
Bharat Biotech & Indian Immunologicals Bharat Biotech to licence Indian Immunologicals
Bharat Biotech & Hester Biosciences Bharat Biotech & Hester Biosciences to sign a CDMO
Panacea
CEPI support the development of multi-epitope, nanoparticle-based
vaccine candidates
Gamaleya
Gamaleya & Gland Pharma To produce 252M doses
Gamaleya & Hetero Biopharma
Gamaleya & Morepen Laboratories
Gamaleya & Panacea Biotec Collaboration discharged
Gamaleya & Stelis Pharma To produce 900M doses
Gamaleya & Virchow Biotech
Gamaleya & Wockhardt
Current industrial initiatives for Covid-19 vaccines in China
Source: CHAI and UNICEF mRNA spokes mRNA plans to 3rd
parties
Fill&Finish End to End
mRNA vaccine development
CSPC ZhongQi Under Ph 2 CT
Fosun Pharma & BioNtech China yet to approve BioNtech vaccine
Walvax Got approval in Indonesia
Everest Medicines & Providence License agreement to produce Covid-19 and other vaccines
Stemirna Therapeutics To develop then produce up to 400M doses
Sinopharm To wait approval to initiate Ph1 CT
CR Pharma & Everest Medicines To establish the company “mRNA&Co” focused on vaccines
discovery
CanSino Under Ph 3 CT
Suzhou Abogen Biosciences Under Ph 1 CT
AIM Vaccine Under Ph 3 CT
Wuhan Recogen Biotechnology Under Ph 1 CT
Other Industrial Partnerships & production
Anhui Zhifei Longcom Under Ph 3 CT
CanSino
Sinovac
Sinopharm
Institute of Medical Biology of
the Chinese Academy of Medical
Sciences
To produce between 500M and 1 billions doses
Shanghai Zerun Bio & Walvax CEPI support to develop COVID-19 multi-variant vaccine
Poly Pharm & Celsion To produce DNA based vaccine
Advaccine & Inovio To produce DNA based vaccine
BioKangtai & AztraZeneca
Rhodiola Bacterin & Gamaleya
Shenzhen Yuanxing Gene-tech &
Gamaleya
To produce 60M doses
TopRidge Pharma & Gamaleya
Hualan Biological Bacterin &
Gamaleya
To produce 100M doses

More Related Content

Similar to Investment_Mapping_v7_web for pharmas manu

Similar to Investment_Mapping_v7_web for pharmas manu (20)

Management of a Pandemic| COVID-19| Canada and the World
Management of a Pandemic| COVID-19| Canada and the World Management of a Pandemic| COVID-19| Canada and the World
Management of a Pandemic| COVID-19| Canada and the World
 
Management of a Pandemic| Analysis and Commentary
Management of a Pandemic| Analysis and CommentaryManagement of a Pandemic| Analysis and Commentary
Management of a Pandemic| Analysis and Commentary
 
How best to Manage a Pandemic - December 6, 2020
How best to Manage a Pandemic - December 6, 2020 How best to Manage a Pandemic - December 6, 2020
How best to Manage a Pandemic - December 6, 2020
 
Management of a Pandemic Crisis
Management of a Pandemic CrisisManagement of a Pandemic Crisis
Management of a Pandemic Crisis
 
Management of a Virus| COVID19
Management of a Virus| COVID19Management of a Virus| COVID19
Management of a Virus| COVID19
 
HealthBIO 2020_Tero Piispanen_Turku Science Park
HealthBIO 2020_Tero Piispanen_Turku Science ParkHealthBIO 2020_Tero Piispanen_Turku Science Park
HealthBIO 2020_Tero Piispanen_Turku Science Park
 
How best to Management a Pandemic - December 1, 2020
How best to Management a Pandemic - December 1, 2020 How best to Management a Pandemic - December 1, 2020
How best to Management a Pandemic - December 1, 2020
 
How best to Management a Pandemic| Geopolitical Event| November 25, 2020
How best to Management a Pandemic| Geopolitical Event| November 25, 2020 How best to Management a Pandemic| Geopolitical Event| November 25, 2020
How best to Management a Pandemic| Geopolitical Event| November 25, 2020
 
Management of Pandemic
Management of PandemicManagement of Pandemic
Management of Pandemic
 
Race for COVID19 Vaccines and Treatments
Race for COVID19 Vaccines and TreatmentsRace for COVID19 Vaccines and Treatments
Race for COVID19 Vaccines and Treatments
 
Management of Pandemic| November 19, 2020| Analysis
Management of Pandemic| November 19, 2020| AnalysisManagement of Pandemic| November 19, 2020| Analysis
Management of Pandemic| November 19, 2020| Analysis
 
Race for COVID19 Vaccine and Treatments
Race for COVID19 Vaccine and TreatmentsRace for COVID19 Vaccine and Treatments
Race for COVID19 Vaccine and Treatments
 
Management a virus
Management a virusManagement a virus
Management a virus
 
COVID19| What's next
COVID19| What's nextCOVID19| What's next
COVID19| What's next
 
Biotech areas
Biotech areasBiotech areas
Biotech areas
 
Covid 19 Vaccination SCM Analysis
Covid 19 Vaccination SCM AnalysisCovid 19 Vaccination SCM Analysis
Covid 19 Vaccination SCM Analysis
 
Fertigo Presentation
Fertigo PresentationFertigo Presentation
Fertigo Presentation
 
How to best Managed a Pandemic| Crisis Management
How to best Managed a Pandemic| Crisis Management How to best Managed a Pandemic| Crisis Management
How to best Managed a Pandemic| Crisis Management
 
vaccination
vaccinationvaccination
vaccination
 
How best to Manage a Pandemic| January 25, 2021
How best to Manage a Pandemic| January 25, 2021How best to Manage a Pandemic| January 25, 2021
How best to Manage a Pandemic| January 25, 2021
 

More from ssuser796efb

More from ssuser796efb (6)

VICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptxVICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptx
 
2) Presentation_Overview_ISO_16140-3_Method_verification_20210322.pptx
2) Presentation_Overview_ISO_16140-3_Method_verification_20210322.pptx2) Presentation_Overview_ISO_16140-3_Method_verification_20210322.pptx
2) Presentation_Overview_ISO_16140-3_Method_verification_20210322.pptx
 
Figure.pptx
Figure.pptxFigure.pptx
Figure.pptx
 
Dr_N_Dharmadhikari_-QbD_in_Product_Development.ppt
Dr_N_Dharmadhikari_-QbD_in_Product_Development.pptDr_N_Dharmadhikari_-QbD_in_Product_Development.ppt
Dr_N_Dharmadhikari_-QbD_in_Product_Development.ppt
 
boccardi_analitytical-procedures.pdf
boccardi_analitytical-procedures.pdfboccardi_analitytical-procedures.pdf
boccardi_analitytical-procedures.pdf
 
Lehninger_Ch1_Introduction.ppt
Lehninger_Ch1_Introduction.pptLehninger_Ch1_Introduction.ppt
Lehninger_Ch1_Introduction.ppt
 

Recently uploaded

Structuring Teams and Portfolios for Success
Structuring Teams and Portfolios for SuccessStructuring Teams and Portfolios for Success
Structuring Teams and Portfolios for Success
UXDXConf
 
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Peter Udo Diehl
 

Recently uploaded (20)

Structuring Teams and Portfolios for Success
Structuring Teams and Portfolios for SuccessStructuring Teams and Portfolios for Success
Structuring Teams and Portfolios for Success
 
Speed Wins: From Kafka to APIs in Minutes
Speed Wins: From Kafka to APIs in MinutesSpeed Wins: From Kafka to APIs in Minutes
Speed Wins: From Kafka to APIs in Minutes
 
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi IbrahimzadeFree and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
 
AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101
 
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
 
Designing for Hardware Accessibility at Comcast
Designing for Hardware Accessibility at ComcastDesigning for Hardware Accessibility at Comcast
Designing for Hardware Accessibility at Comcast
 
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdfSimplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
 
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfIntroduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
 
ECS 2024 Teams Premium - Pretty Secure
ECS 2024   Teams Premium - Pretty SecureECS 2024   Teams Premium - Pretty Secure
ECS 2024 Teams Premium - Pretty Secure
 
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
 
Syngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdfSyngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdf
 
Demystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John StaveleyDemystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John Staveley
 
PLAI - Acceleration Program for Generative A.I. Startups
PLAI - Acceleration Program for Generative A.I. StartupsPLAI - Acceleration Program for Generative A.I. Startups
PLAI - Acceleration Program for Generative A.I. Startups
 
IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024
 
IESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIESVE for Early Stage Design and Planning
IESVE for Early Stage Design and Planning
 
Where to Learn More About FDO _ Richard at FIDO Alliance.pdf
Where to Learn More About FDO _ Richard at FIDO Alliance.pdfWhere to Learn More About FDO _ Richard at FIDO Alliance.pdf
Where to Learn More About FDO _ Richard at FIDO Alliance.pdf
 
Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)
Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)
Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)
 
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfThe Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
 
Top 10 Symfony Development Companies 2024
Top 10 Symfony Development Companies 2024Top 10 Symfony Development Companies 2024
Top 10 Symfony Development Companies 2024
 
Strategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering TeamsStrategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering Teams
 

Investment_Mapping_v7_web for pharmas manu

  • 2. Afrigen South African hub + Biovac Institute Pasteur Tunis - Tunisia BioGeneric Pharma – Egypt TBD - Kenya nstitute Pasteur Dakar - Senegal Biovaccines - Nigeria end-to-end Spokes & Current industrial initiatives for Covid-19 vaccines in Africa Fill&Finish mRNA plans to 3rd parties mRNA spokes Algeria Morocco Ghana Uganda Rwanda Source: CHAI and UNICEF Botswana mRNA vaccine production Kenya Moderna Moderna and Kenya signed a MoU to build mRNA facility Rwanda Senegal, South Africa BioNTech BioNTech announced a plan to develop the capacity to produce upcoming mRNA-based vaccines Ghana BioNTech BioNTech to establish manufacturing plants for fill, finish and packaging Other Industrial Partnerships Algeria Saidal & Sinovac 200M capacity, started in 2021, then move up the value chain Saidal & Gamaleya Sputnik V starting Sept 2021 ($40M capacity) Sothema & Sinopharm $60M capacity South Africa Aspen & J&J F&F started in 2021. 2022 plan to manufacture under Aspen’s brand name NantSA & Immunity Bio To set up a new plant to produce vaccines Rubic Consortium & Dyadic & WITS to establish a new plant Biovac & Pfizer started a tech transfer in 2021 for AU member states Egypt Eva Pharma EgyVax currently under Ph 1 Vacsera & Sinovac Produced ~30M doses of Sinovac vaccine Minipharma & Gamaleya To produce 40M doses per year Botswana NantWorks to establish a new plant and to produce Corbevax by 2026
  • 3. Financial &Technical contributions to African vaccine local production outside of the mRNA Tech Transfer Hub Institution Content of the support AFD Granted €1.8M to IPD for a feasibility study Afreximbank To support infrastructural facilities and initiate vaccine production in Ogun State, Nigeria for €180M Belgium €4.5M for NRA strengthening in Senegal and €0,5M to Rwanda Germany BMZ (KfW) granted €20M to IPD’s MADIBA project and €1M to develop vaccine production capacity BMZ (GIZ) committed €5M to Ghana to advance local manufacturing + 0.18M +€2.7M co-financing from EU to strengthen the FDA BMZ (GIZ) committed €11.7M for establishing a local vaccine in Rwanda and €24M to support EAC Centre of Excellence for vaccine DEG support to Aspen with €144M (J&J vaccine) €51M to South Africa to support vaccination campaigns and the development of a vaccine supply chain (incl. regulatory strengthening) €10M to support ACDC and promote regulatory framework €250M promotional loan to Afreximbank + €12.2M to the prep4vac project Institution Content of the support FCDO FCDO supported the business case development and feasibility assessment for Aspen and IPD IFC coalition IPD €13M grant for MADIBA project Rwanda and Morocco to conduct diagnostic and feasibility studies Biovac to raise €136M Aspen contracted €644M loan Team Europe & EU IPD received €6.7M to support the MADIBA project Granted €3.1M to Rwanda US Gov US DFC granted €2.9M to IPD to support the MADIBA project Aspen received €181M to produce J&J vaccine for the African continent World Bank Attributed Granted €27M to Biovaccines for vaccine manufacturing plant
  • 4. Spokes & current industrial initiatives for Covid-19 vaccines in Latin America Source: CHAI and UNICEF mRNA spokes mRNA plans to 3rd parties Fill&Finish End to End Argentina - Sinergium Biotech Brazil – Bio-Manguinho Venezuela Peru Mexico Cuba mRNA vaccine production Brazil HDT Bio & SENAI CIMATEC HDT Bio granted to SENAI CIMATEC a non-exclusive license to produce its RNA vaccine Eurofarma & BioNtech to produce 100M doses Other Industrial Partnerships Argentina Richmond Lab & Gamaleya Research Institute to produce Sputnik mAbxience & AstraZeneca mAbxience to produce AstraZeneca’s drug substance to be FF in Mexico Sinergium & Sinopharm to produce 1M doses /week Brazil Fiocruz & AstraZeneca for 100.4M doses capacity Biomm & CanSino to distribute the vaccine in Brazil União Química & Gamaleya to set up FF capacity Instituto Butantan & Sinovac to produce 1M doses Cuba BioCubaFarma developed Abdala and Soberana 2 vaccine Mexico Birmex & Gamaleya Birmex & AstraZeneca Peru Plans to build a plant in 2023 to produce Sputnik V and other vaccines Venezuela Espromed-Bio & Center for Genetic Engineering and Biotechnology Espromed-Bio to produce 4M doses from the Center for Genetic Engineering and Biotechnology
  • 5. Source: CHAI and UNICEF Pakistan - National Institute of Health Vietnam - Polyvac Bangladesh – Incepta Indonesia - Biofarma Malaysia Sri Lanka Philippines Thailand mRNA spokes mRNA plans to 3rd parties Fill&Finish End to End mRNA vaccine production Bangladesh Globe Biotech to develop its own mRNA vaccines. Under Ph1 Thailand Bionet consortium composed of Pennsylvania, North Carolina, California- Davis, Chulalongkorn, IVI. Currently under Ph 2 CT Vietnam Vinbiocare & Arcturus Other Industrial Partnerships Bangladesh Incepta to produce Corbevax Incepta & Sinopharme MoU to produce 5M doses Indonesia Bio Farma & Children’s Hospital to produce Texas Children’s Hospital’ vaccine Bio Farma & Sinovac Malaysia Pharmaniaga & Sinovac to distribute then produce 14M doses Solution Biologic & Cansino Philippines Glovax Biotech & Eubiologics to produce 40M doses Sri Lanka State Pharmaceutical Corporation & Sinovac to produce 9M doses Thailand Siam Bioscience & AstraZeneca Vietnam IVAC stops Ph 3 CT of its COVIVAC due to volunteer shortages IVAC & CIGB to produce Cuban Abdala vaccine Nanogen to develop a recombinant vaccine that is still under Ph 3 trial Vabiotech & Gamaleya Vabiotech& Shionogi AIC & Shionogi Polyvac & Gamaleya
  • 6. Current industrial initiatives for Covid-19 vaccines in India Source: CHAI and UNICEF mRNA spokes mRNA plans to 3rd parties Fill&Finish End to End Drug substance mRNA vaccine production Gennova Gennova Gennova is developing mRNA vaccine Other Industrial Partnerships Biological E Biological E & Texas Children’s Hospital Biological E & J&J Biological E & J&J to collaborate to produce 600M doses/year Serum Institute of India SII & Novavax SII & Gamaleya Research Institute SII & AstraZeneca Bharat Biotech Bharat Biotech To develop an inactivated vaccine Bharat Biotech & Haffkine Bharat Biotech to licence Haffkine Bharat Biotech & Indian Immunologicals Bharat Biotech to licence Indian Immunologicals Bharat Biotech & Hester Biosciences Bharat Biotech & Hester Biosciences to sign a CDMO Panacea CEPI support the development of multi-epitope, nanoparticle-based vaccine candidates Gamaleya Gamaleya & Gland Pharma To produce 252M doses Gamaleya & Hetero Biopharma Gamaleya & Morepen Laboratories Gamaleya & Panacea Biotec Collaboration discharged Gamaleya & Stelis Pharma To produce 900M doses Gamaleya & Virchow Biotech Gamaleya & Wockhardt
  • 7. Current industrial initiatives for Covid-19 vaccines in China Source: CHAI and UNICEF mRNA spokes mRNA plans to 3rd parties Fill&Finish End to End mRNA vaccine development CSPC ZhongQi Under Ph 2 CT Fosun Pharma & BioNtech China yet to approve BioNtech vaccine Walvax Got approval in Indonesia Everest Medicines & Providence License agreement to produce Covid-19 and other vaccines Stemirna Therapeutics To develop then produce up to 400M doses Sinopharm To wait approval to initiate Ph1 CT CR Pharma & Everest Medicines To establish the company “mRNA&Co” focused on vaccines discovery CanSino Under Ph 3 CT Suzhou Abogen Biosciences Under Ph 1 CT AIM Vaccine Under Ph 3 CT Wuhan Recogen Biotechnology Under Ph 1 CT Other Industrial Partnerships & production Anhui Zhifei Longcom Under Ph 3 CT CanSino Sinovac Sinopharm Institute of Medical Biology of the Chinese Academy of Medical Sciences To produce between 500M and 1 billions doses Shanghai Zerun Bio & Walvax CEPI support to develop COVID-19 multi-variant vaccine Poly Pharm & Celsion To produce DNA based vaccine Advaccine & Inovio To produce DNA based vaccine BioKangtai & AztraZeneca Rhodiola Bacterin & Gamaleya Shenzhen Yuanxing Gene-tech & Gamaleya To produce 60M doses TopRidge Pharma & Gamaleya Hualan Biological Bacterin & Gamaleya To produce 100M doses